GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » EV-to-FCF

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) EV-to-FCF : -0.70 (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Paradigm Biopharmaceuticals's Enterprise Value is $36.59 Mil. Paradigm Biopharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-52.56 Mil. Therefore, Paradigm Biopharmaceuticals's EV-to-FCF for today is -0.70.

The historical rank and industry rank for Paradigm Biopharmaceuticals's EV-to-FCF or its related term are showing as below:

PBIGF' s EV-to-FCF Range Over the Past 10 Years
Min: -13.87   Med: 0   Max: 0
Current: -0.78

PBIGF's EV-to-FCF is ranked worse than
100% of 376 companies
in the Biotechnology industry
Industry Median: 9.49 vs PBIGF: -0.78

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Paradigm Biopharmaceuticals's stock price is $0.19. Paradigm Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.156. Therefore, Paradigm Biopharmaceuticals's PE Ratio for today is At Loss.


Paradigm Biopharmaceuticals EV-to-FCF Historical Data

The historical data trend for Paradigm Biopharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals EV-to-FCF Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial -29.79 -59.18 -11.80 -5.76 -4.93

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -5.76 - -4.93 -

Competitive Comparison of Paradigm Biopharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paradigm Biopharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's EV-to-FCF falls into.



Paradigm Biopharmaceuticals EV-to-FCF Calculation

Paradigm Biopharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=36.591/-52.563
=-0.70

Paradigm Biopharmaceuticals's current Enterprise Value is $36.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paradigm Biopharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-52.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paradigm Biopharmaceuticals  (OTCPK:PBIGF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Paradigm Biopharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.19/-0.156
=At Loss

Paradigm Biopharmaceuticals's share price for today is $0.19.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paradigm Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.156.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Paradigm Biopharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Headlines

From GuruFocus